11.78

1.59% -0.15

Urogen Pharma Ltd (URGN)

Overview News Price History Option Chain Financials Discussions Forecast

Urogen Pharma Ltd stock is traded at $11.78, with a volume of 266.66K. It is down -1.59% in the last 24 hours and down -7.56% over the past month. UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Previous Close:

$11.93

Open:

$11.93

24h Volume:

266.66K

Relative Volume:

0.47

Market Cap:

$508.32M

Revenue:

$82.71M

Net Income/Loss:

$-102.24M

P/E Ratio:

-2.5171

EPS:

-4.68

Net Cash Flow:

$-76.57M

1W Performance:

-4.16%

1M Performance:

-7.56%

6M Performance:

-17.90%

1Y Performance:

+1.47%

1-Day Range:

$11.65

$12.30

1-Week Range:

$11.65

$13.33

52-Week Range:

$10.60

$20.70

Urogen Pharma Ltd Stock (URGN) Company Profile

Name

Urogen Pharma Ltd

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

972 9 770 7601

Address

9 HA'TA'ASIYA ST, RA'ANANA

Employee

203

Twitter

@UroGenPharma

Next Earnings Date

2024-11-06

Latest SEC Filings

URGN's Discussions on Twitter

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-08-23	Downgrade	Jefferies	Buy → Hold
Apr-27-22	Initiated	Berenberg	Buy
Apr-16-20	Reiterated	H.C. Wainwright	Buy
Apr-13-20	Reiterated	H.C. Wainwright	Buy
Jan-09-20	Initiated	National Securities	Neutral
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy
Nov-15-17	Reiterated	Oppenheimer	Outperform
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

View All

Urogen Pharma Ltd Stock (URGN) Latest News

08:00 AM

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference - StockTitan

08:00 AM

Nov 04, 2024

(URGN) Investment Analysis - Stock Traders Daily

Nov 04, 2024

Nov 02, 2024

Rice Hall James & Associates LLC Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

Nov 02, 2024

Oct 31, 2024

UroGen Pharma (URGN) to Release Quarterly Earnings on Wednesday - MarketBeat

Oct 31, 2024

Oct 30, 2024

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - BioSpace

Oct 30, 2024

Oct 28, 2024

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - StockTitan

Oct 28, 2024

Oct 25, 2024

(URGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 25, 2024

Oct 21, 2024

UroGen started at buy by EF Hutton, RTGel technology cited - MSN

Oct 21, 2024

Oct 19, 2024

Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years - Yahoo Finance

Oct 19, 2024

Oct 17, 2024

FDA accepts UroGen's NDA for bladder cancer treatment - Investing.com India

Oct 17, 2024

Oct 16, 2024

When Would Be The Best Time To Buy UroGen Pharma Ltd (NASDAQ: URGN) Stock? - Stocks Register

Oct 16, 2024

URGN’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle

Oct 16, 2024

UroGen Pharma maintains Outperform stock rating on new drug application - Investing.com

Oct 16, 2024